Literature DB >> 12843318

Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain.

S Kudo1, Y Nomura, M Segawa, N Fujita, M Nakao, C Schanen, M Tamura.   

Abstract

Rett syndrome is a neurodevelopmental disorder with severe mental retardation caused by mutations in the MECP2 gene. Mutations in the MECP2 gene are also associated with other genetic disorders, including X linked mental retardation in males. Missense mutations identified so far are present primarily in the methyl CpG binding domain (MBD) of MECP2. Here, the functional significance of 28 MBD missense mutations identified in patients were analysed by transient expression of the mutant proteins in cultured cells. The effects of mutations were evaluated by analysis of the affinity of MeCP2 to pericentromeric heterochromatin in mouse L929 cells and on transcriptional repressive activity of MeCP2 in Drosophila SL2 cells. These analyses showed that approximately one-third (9/28) of MBD missense mutations showed strong impairment of MeCP2 function. The mutation of the R111 residue, which directly interacts with the methyl group of methyl cytosine, completely abolished MeCP2 function and mutations affecting beta-sheets and a hairpin loop have substantial functional consequences. In contrast, mutations that showed marginal or mild impairment of the function fell in unstructured regions with no DNA interaction. Since each of these mutations is known to be pathogenic, the mutations may indicate residues that are important for specific functions of MeCP2 in neurones.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843318      PMCID: PMC1735522          DOI: 10.1136/jmg.40.7.487

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  48 in total

1.  Classic Rett syndrome in a boy as a result of somatic mosaicism for a MECP2 mutation.

Authors:  J Armstrong; M Pineda; E Aibar; E Geán; E Monrós
Journal:  Ann Neurol       Date:  2001-11       Impact factor: 10.422

2.  Functional analyses of MeCP2 mutations associated with Rett syndrome using transient expression systems.

Authors:  S Kudo; Y Nomura; M Segawa; N Fujita; M Nakao; J Dragich; C Schanen; M Tamura
Journal:  Brain Dev       Date:  2001-12       Impact factor: 1.961

3.  Functional characterisation of MeCP2 mutations found in male patients with X linked mental retardation.

Authors:  S Kudo; Y Nomura; M Segawa; N Fujita; M Nakao; S Hammer; C Schanen; I Terai; M Tamura
Journal:  J Med Genet       Date:  2002-02       Impact factor: 6.318

4.  Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice.

Authors:  R Z Chen; S Akbarian; M Tudor; R Jaenisch
Journal:  Nat Genet       Date:  2001-03       Impact factor: 38.330

5.  Mutation spectrum in patients with Rett syndrome in the German population: Evidence of hot spot regions.

Authors:  F Laccone; P Huppke; F Hanefeld; M Meins
Journal:  Hum Mutat       Date:  2001-03       Impact factor: 4.878

6.  A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome.

Authors:  J Guy; B Hendrich; M Holmes; J E Martin; A Bird
Journal:  Nat Genet       Date:  2001-03       Impact factor: 38.330

7.  Preserved speech variants of the Rett syndrome: molecular and clinical analysis.

Authors:  M Zappella; I Meloni; I Longo; G Hayek; A Renieri
Journal:  Am J Med Genet       Date:  2001-11-15

8.  Development of language in Rett syndrome.

Authors:  J Uchino; M Suzuki; K Hoshino; Y Nomura; M Segawa
Journal:  Brain Dev       Date:  2001-12       Impact factor: 1.961

9.  Rett syndrome in Spain: mutation analysis and clinical correlations.

Authors:  E Monrós; J Armstrong; E Aibar; P Poo; I Canós; M Pineda
Journal:  Brain Dev       Date:  2001-12       Impact factor: 1.961

10.  Mutation analysis of the methyl-CpG-binding protein 2 gene (MECP2) in Rett patients with preserved speech.

Authors:  Y Yamashita; I Kondo; T Fukuda; R Morishima; A Kusaga; R Iwanaga; T Matsuishi
Journal:  Brain Dev       Date:  2001-12       Impact factor: 1.961

View more
  35 in total

1.  Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations.

Authors:  Christopher A Chapleau; Gaston D Calfa; Meredith C Lane; Asher J Albertson; Jennifer L Larimore; Shinichi Kudo; Dawna L Armstrong; Alan K Percy; Lucas Pozzo-Miller
Journal:  Neurobiol Dis       Date:  2009-05-12       Impact factor: 5.996

Review 2.  Experimental models of Rett syndrome based on Mecp2 dysfunction.

Authors:  Gaston Calfa; Alan K Percy; Lucas Pozzo-Miller
Journal:  Exp Biol Med (Maywood)       Date:  2011-01

3.  The nuclear structural protein NuMA is a negative regulator of 53BP1 in DNA double-strand break repair.

Authors:  Naike Salvador Moreno; Jing Liu; Karen M Haas; Laurie L Parker; Chaitali Chakraborty; Stephen J Kron; Kurt Hodges; Lance D Miller; Carl Langefeld; Paul J Robinson; Sophie A Lelièvre; Pierre-Alexandre Vidi
Journal:  Nucleic Acids Res       Date:  2019-04-08       Impact factor: 16.971

Review 4.  Interpreting the language of histone and DNA modifications.

Authors:  Scott B Rothbart; Brian D Strahl
Journal:  Biochim Biophys Acta       Date:  2014-03-12

Review 5.  Rett syndrome and MeCP2.

Authors:  Vichithra R B Liyanage; Mojgan Rastegar
Journal:  Neuromolecular Med       Date:  2014-03-11       Impact factor: 3.843

6.  A novel hypomorphic MECP2 point mutation is associated with a neuropsychiatric phenotype.

Authors:  Abidemi A Adegbola; Michael L Gonzales; Andrew Chess; Janine M LaSalle; Gerald F Cox
Journal:  Hum Genet       Date:  2008-11-07       Impact factor: 4.132

7.  Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations.

Authors:  Jennifer L Larimore; Christopher A Chapleau; Shinichi Kudo; Anne Theibert; Alan K Percy; Lucas Pozzo-Miller
Journal:  Neurobiol Dis       Date:  2009-01-03       Impact factor: 5.996

Review 8.  The role of MeCP2 in brain development and neurodevelopmental disorders.

Authors:  Michael L Gonzales; Janine M LaSalle
Journal:  Curr Psychiatry Rep       Date:  2010-04       Impact factor: 5.285

9.  Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor.

Authors:  Matthew J Lyst; Robert Ekiert; Daniel H Ebert; Cara Merusi; Jakub Nowak; Jim Selfridge; Jacky Guy; Nathaniel R Kastan; Nathaniel D Robinson; Flavia de Lima Alves; Juri Rappsilber; Michael E Greenberg; Adrian Bird
Journal:  Nat Neurosci       Date:  2013-06-16       Impact factor: 24.884

10.  A temporal threshold for formaldehyde crosslinking and fixation.

Authors:  Lars Schmiedeberg; Pete Skene; Aimée Deaton; Adrian Bird
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.